Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Peter A Gottlieb"'
Autor:
Laura M. Jacobsen, Jennifer L. Sherr, Elizabeth Considine, Angela Chen, Sarah M. Peeling, Margo Hulsmans, Sara Charleer, Marzhan Urazbayeva, Mustafa Tosur, Selma Alamarie, Maria J. Redondo, Korey K. Hood, Peter A. Gottlieb, Pieter Gillard, Jessie J. Wong, Irl B. Hirsch, Richard E. Pratley, Lori M. Laffel, Chantal Mathieu, ADA/EASD PMDI
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-24 (2023)
Abstract Background The greatest change in the treatment of people living with type 1 diabetes in the last decade has been the explosion of technology assisting in all aspects of diabetes therapy, from glucose monitoring to insulin delivery and decis
Externí odkaz:
https://doaj.org/article/58b9c96d2c334d6da4dd72be5fec5eec
Autor:
Angela M. Mitchell, Erin E. Baschal, Kristen A. McDaniel, Kimber M. Simmons, Laura Pyle, Kathleen Waugh, Andrea K. Steck, Liping Yu, Peter A. Gottlieb, Marian J. Rewers, Maki Nakayama, Aaron W. Michels
Publikováno v:
JCI Insight, Vol 7, Iss 18 (2022)
T cell receptor (TCR) sequences are exceptionally diverse and can now be comprehensively measured with next-generation sequencing technologies. However, a thorough investigation of longitudinal TCR repertoires throughout childhood in health and durin
Externí odkaz:
https://doaj.org/article/fdd60e79e23f4d1292274bdb7907007f
Autor:
Zachary C. Stensland, Brianne M. Coleman, Marynette Rihanek, Ryan M. Baxter, Peter A. Gottlieb, Elena W.Y. Hsieh, Virginia D. Sarapura, Kimber M. Simmons, John C. Cambier, Mia J. Smith
Publikováno v:
iScience, Vol 25, Iss 1, Pp 103626- (2022)
Summary: Autoimmune thyroid disease (AITD) is caused by aberrant activation of the immune system allowing autoreactive B and T cells to target the thyroid gland leading to disease. Although AITD is more frequently diagnosed in adults, children are al
Externí odkaz:
https://doaj.org/article/30cb121fcd7e4390ab3193f5172a949c
Autor:
Zachary C. Stensland, Christopher A. Magera, Hali Broncucia, Brittany D. Gomez, Nasha M. Rios-Guzman, Kristen L. Wells, Catherine A. Nicholas, Marynette Rihanek, Maya J. Hunter, Kevin P. Toole, Peter A. Gottlieb, Mia J. Smith
Publikováno v:
Journal of Experimental Medicine. 220
Recent evidence suggests a role for B cells in the pathogenesis of young-onset type 1 diabetes (T1D), wherein rapid progression occurs. However, little is known regarding the specificity, phenotype, and function of B cells in young-onset T1D. We perf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3db6dce1c3d3ce1b7eefa7a639af6ff3
https://doi.org/10.1084/jem.20221604
https://doi.org/10.1084/jem.20221604
Autor:
Laura M. Jacobsen, Jennifer L. Sherr, Elizabeth Considine, Angela Chen, Sarah Peeling, Margo Hulsmans, Sara Charleer, Marzhan Urazbayeva, Mustafa Tosur, Selma Alamarie, Maria J. Redondo, Korey K. Hood, Peter A. Gottlieb, Pieter Gillard, Jessie J. Wong, Irl B. Hirsch, Richard E. Pratley, Lori Laffel, Chantal Mathieu
The greatest change in the treatment of people living with type 1 diabetes in the last decade has been the explosion of technology assisting in all aspects of diabetes therapy, from glucose monitoring to insulin delivery and decision making. Through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d217bd5776a4fc40a6331e228f3c99b
https://doi.org/10.1101/2023.04.15.23288624
https://doi.org/10.1101/2023.04.15.23288624
Autor:
Kevan C. Herold, Anette-Gabriele Ziegler, Darrell M. Wilson, Diane K. Wherrett, John M Wentworth, Jay S. Skyler, Phillip Raskin, Andrew B. Muir, Antoinette M. Moran, Wayne V Moore, Daniel J. Moore, Sandra M. Lord, S. Alice Long, Peter S. Linsley, Ingrid M. Libman, Jeffrey P Krischer, Michael J. Haller, Carla J. Greenbaum, Peter A. Gottlieb, Robin S. Goland, Stephen E. Gitelman, Laura A. Cooney, Mark S. Anderson, Brian N. Bundy, William E. Russell
Objective Previous studies showed that inhibiting lymphocyte costimulation reduces declining beta cell function in individuals newly-diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e612bbc18c514cf7dd93b604e719af2d
https://doi.org/10.2337/figshare.22009586
https://doi.org/10.2337/figshare.22009586
Autor:
Mara Kinney, Lu You, Emily K Sims, Diane Wherrett, Desmond Schatz, Sandra Lord, Jeffrey Krischer, William E Russell, Peter A Gottlieb, Ingrid Libman, Jane Buckner, Linda A DiMeglio, Kevan C Herold, Andrea K Steck
Publikováno v:
Journal of the Endocrine Society. 7
Context Participants with stage 1 or 2 type 1 diabetes (T1D) qualify for prevention trials, but factors involved in screening for such trials are largely unknown. Objective To identify factors associated with screening for T1D prevention trials. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::462be242463d95a4ea7071f2e47ee527
https://doi.org/10.1210/jendso/bvad003
https://doi.org/10.1210/jendso/bvad003
Autor:
Peter A. Gottlieb, Taylor K. Armstrong, Liping Yu, Andrea K. Steck, Hali C. Broncucia, Taylor M. Triolo, Laura Pyle
Publikováno v:
J Clin Endocrinol Metab
Objective Electrochemiluminescence (ECL) assays are high-affinity autoantibody (Ab) tests that are more specific than Abs detected by traditional radiobinding assays (RBA) for risk screening and prediction of progression to type 1 diabetes. We sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0170d7002611843585520f581f2a03cc
https://doi.org/10.1210/clinem/dgab853
https://doi.org/10.1210/clinem/dgab853
Autor:
Stephen E. Gitelman, Desmond A. Schatz, Mark A. Atkinson, Jasmine A Mack, Laura M. Jacobsen, Brittany S. Bruggeman, Amanda L. Posgai, Peter A. Gottlieb, Michael J. Haller, Andrea Lin, Matthew J. Gurka, Todd M. Brusko, Clayton E. Mathews, Clive Wasserfall
Publikováno v:
Diabetes, vol 70, iss 5
Diabetes
Diabetes
Previously, we demonstrated low-dose anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) immunotherapy preserved C-peptide for two years in a pilot study of subjects with established type 1 diabetes (n=25). Herein, we evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de47f384d13030523c56ef87d2143061
https://doi.org/10.2337/db20-1103
https://doi.org/10.2337/db20-1103
Autor:
Kevan C. Herold, Peter A. Gottlieb, Louis H. Philipson, James Dziura, David A. Baidal, Ruth S. Weinstock, Jason L. Gaglia, Rodica Pop-Busui, Jennifer B. Marks, Stephen E. Gitelman, Jesse Reynolds
Publikováno v:
Diabetes, obesity & metabolism, vol 22, iss 11
Diabetes Obes Metab
Diabetes Obes Metab
AIMS: To test whether a long-acting GLP-1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c923f3404bac8533ff93ea3c5316af
https://doi.org/10.1111/dom.14121
https://doi.org/10.1111/dom.14121